Skip to main content

ORIGINAL RESEARCH article

Front. Cardiovasc. Med.
Sec. Coronary Artery Disease
Volume 12 - 2025 | doi: 10.3389/fcvm.2025.1492569
This article is part of the Research Topic Optimizing Revascularization and Conservative Therapy in Chronic Coronary Syndrome View all 6 articles

Effect of Ticagrelor Combined with Metoprolol Extended-Release Tablets on Cardiac Function and Clinical Prognosis in Elderly Patients with Acute Coronary Syndrome After Percutaneous Coronary Intervention

Provisionally accepted
Lili Wang Lili Wang Linlin Gao Linlin Gao Qin Chen Qin Chen Chen Li Chen Li Hui Xu Hui Xu Ling Sun Ling Sun Youbin Hu Youbin Hu *
  • Taizhou Jiangyan Hospital of Traditional Chinese Medicine, Taizhou, China

The final, formatted version of the article will be published soon.

    Background: Acute coronary syndrome (ACS) poses significant risks to older individuals. This study sought to assess the impact of combining ticagrelor and metoprolol extended-release tablets on clinical prognosis and cardiac function in elderly ACS patients following percutaneous coronary intervention (PCI).Methods: From February 2022 to February 2023, 90 elderly ACS patients who underwent PCI at our institution were retrospectively enrolled and divided into two groups: an observation group (OG) and a control group (CG), with 45 patients in each group. The CG received oral metoprolol extended-release tablets, while the OG received both oral metoprolol extended-release tablets and ticagrelor. Prognostic indicators and cardiac function were evaluated before and after treatment.The treatment effectiveness rate in the OG was 97.78%, significantly higher than the CG's rate of 77.78% (P < 0.05). Post-treatment, the OG displayed notable improvements in cardiac function, including significantly higher left ventricular ejection fraction (LVEF), stroke volume (SV), cardiac output (CO), and cardiac index (CI) compared to the CG (P < 0.05). Both groups experienced enhanced exercise capacity, as evidenced by longer exercise duration (ED) and improved 6-minute walking test (6MWT) results, with the OG showing superior gains (P < 0.05).Additionally, the OG had significantly higher serum levels of cardiac troponin T (cTnT) and creatine kinase isoenzyme (CK-MB) than the CG (P < 0.05). Decreases in serum levels of sICAM-1, MMP-9, and hs-CRP were observed in both groups, with more pronounced improvements in the OG (P < 0.05). The incidence of adverse prognostic events in the OG was significantly lower at 8.89%, compared to 37.78% in the CG (P < 0.05).Ticagrelor combined with metoprolol extended-release tablets can significantly improve cardiac function, motor performance, and quality of life in ACS patients after PCI. Additionally, it effectively increases myocardial injury markers and reduces serum inflammatory factor levels.

    Keywords: ticagrelor, Metoprolol extended-release tablets, Acute Coronary Syndrome, Percutaneous Coronary Intervention, cardiac function, Clinical prognosis

    Received: 07 Sep 2024; Accepted: 13 Jan 2025.

    Copyright: © 2025 Wang, Gao, Chen, Li, Xu, Sun and Hu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Youbin Hu, Taizhou Jiangyan Hospital of Traditional Chinese Medicine, Taizhou, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.